Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7589)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 15, 2023 (publication date) through Mar 22, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(11): 1900-1912 [PMID: 38077640 DOI: 10.4251/wjgo.v15.i11.1900] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(11): 1900-1912 [PMID: 38077640 DOI: 10.4251/wjgo.v15.i11.1900] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i11/1900.htm |
| Number | Citing Articles |
| 1 |
Peishuang Xu, Chang Hong, Li Liu, Lushan Xiao. PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2025; 1880(3): 189334 doi: 10.1016/j.bbcan.2025.189334
|
| 2 |
Huanquan Chen, Tianxing Dai, Jie Gao, Chuanjiang Li, Huanwei Chen, Feiwen Deng, Nan Ma, Guoying Wang. Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy. Organ Medicine 2026; 3(1): 12 doi: 10.1002/orm2.70034
|
| 3 |
Ken Horisaki, Shusuke Yoshikawa, Shoichiro Mori, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara. Prognostic value of the CONUT score with immune checkpoint inhibitors as first‐line therapy for metastatic malignant melanoma. The Journal of Dermatology 2025; 52(4): 615 doi: 10.1111/1346-8138.17613
|
| 4 |
Panpan Jiao, Lijuan Xue, Weijuan Tan, Quan Chen, Shan Lin, Min Song, Chunling Ma, Juan Zhan. Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐PD‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital. Cancer Medicine 2026; 15(2) doi: 10.1002/cam4.71603
|
| 5 |
Yunyi Du, Ying Zhang, Wenqi Zhao, Yuexiang Zhang, Fei Su, Xiaoling Zhang, Weiling Li, Wenqing Hu, Yongai Li, Jun Zhao. Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy. Human Vaccines & Immunotherapeutics 2024; 20(1) doi: 10.1080/21645515.2024.2398309
|
| 6 |
Ryo Morikawa, Kentaro Nitta, Shuntaro Yasuda, Yoshihito Kano, Rika Noji, Satoru Aoyama, Shingo Sato, Sadakatsu Ikeda, Ryuichi Okamoto, Masashi Nagata, Takehiko Mori, Mitsukuni Suenaga. Identification of risk factors for gastrointestinal immune–related adverse events associated with immune check point inhibitors. Expert Opinion on Drug Safety 2024; : 1 doi: 10.1080/14740338.2024.2443955
|
| 7 |
Xinyu Zhang, Bei Zhang, Danfei Li, Yunchao Yang, Sen Lin, Ruiqi Zhao, Yijia Li, Lisheng Peng. Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1528084
|
| 8 |
Dongming Liu, Norihiro Imai. Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care. Cancers 2025; 17(19): 3105 doi: 10.3390/cancers17193105
|
| 9 |
Qiu-Yu Jiang, Ru-Yi Xue. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events. World Journal of Gastrointestinal Oncology 2024; 16(3): 577-582 doi: 10.4251/wjgo.v16.i3.577
Abstract(664) |
Core Tip(605) |
Full Article(HTML)(2421)
|
Full Article with Cover (PDF)-650K(143)
|
Full Article (Word)-119K(48)
|
Audio-472K(15)
|
Peer-Review Report-215K(146)
|
Answering Reviewers-117K(150)
|
Full Article (PDF)-382K(158)
|
Full Article (XML)-145K(132)
|
Times Cited (3)
|
Total Visits (6207)
|
Open
|
| 10 |
Mark D Willis, Ben Schroeder, Laura Marandino, Samra Turajlic, Aisling S Carr. Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist. Journal of Neurology, Neurosurgery & Psychiatry 2025; 96(11): 1024 doi: 10.1136/jnnp-2025-335998
|
| 11 |
Zhenli Li, Tiezhu Yao, Guang Liu, Zhengkun Guan, Jing Liu, Ling Guo, Jingtao Ma. Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis. Journal of Cancer Research and Clinical Oncology 2024; 150(5) doi: 10.1007/s00432-024-05801-7
|
| 12 |
Yaser Soleimani, Seyedehhoda Khatibmasjedi, Seyed Alireza Javadinia, Sara Shenavaei Zare, Reza Chaman. Editorial for “a predictive model for irAEs in ESCC patients treated with PD-1 inhibitors based on blood indicators”. Future Science OA 2025; 11(1) doi: 10.1080/20565623.2025.2527486
|
| 13 |
Tai-Xin Yang, Jia-Yong Su, Min-Jun Li, Shuang Shen, Yu Wang, Huan-Nan Wei, Ming-Jian Huang, Qing-Man Qin, You-Yin Ran, Yao-Ting Huang, Jin-Yan Huang, Bang-De Xiang, Jie Zhang, Wen-Feng Gong. Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1640075
|
| 14 |
Qiang Zhao, Liang Wang, Xun Yang, Jifeng Feng, Qixun Chen. Association of the Scottish inflammatory prognostic score with treatment-related adverse events and prognosis in esophageal cancer receiving neoadjuvant immunochemotherapy. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1418286
|
| 15 |
Mathew Vithayathil, Deniz Koku, Claudia Campani, Jean-Charles Nault, Olivier Sutter, Nathalie Ganne-Carrié, Eric O. Aboagye, Rohini Sharma. Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2025; 83(4): 959 doi: 10.1016/j.jhep.2025.04.017
|
| 16 |
Joaquim Faria Monteiro, Alexandrina Fernandes, Diogo Gavina Tato, Elias Moreira, Ricardo Ribeiro, Henrique Reguengo, Jorge Gonçalves, Paula Fresco. Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring. Cancers 2025; 17(19): 3262 doi: 10.3390/cancers17193262
|
| 17 |
Zeyu Yu, Ran You, Chendong Wang, Bin Leng, Lingfeng Diao, Qingyu Xu, Guowen Yin. A baseline-lymphocyte-subset nomogram for predicting severe immune-related adverse events in hepatocellular carcinoma patients receiving TACE plus immunotherapy. Hepatoma Research 2025; doi: 10.20517/2394-5079.2025.47
|
| 18 |
Qian Wang, Tingting Wu, Ru Zhao, Yuanqin Li, Xuetao Chen, Shanmei Shen, Xiaowen Zhang. Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy. Endocrine Practice 2024; 30(10): 943 doi: 10.1016/j.eprac.2024.07.006
|
| 19 |
Jie Liao. Comparison of immune-related adverse events and analysis of risk factors in older and younger rectal cancer patients receiving immunotherapy. American Journal of Cancer Research 2025; 15(5): 2153 doi: 10.62347/QLFX5040
|
| 20 |
Mathew Vithayathil, Giulia Francesca Manfredi, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Ciro Celsa, Pasquale Lombardi, Aria Torkpour, Bernardo Stefanini, Peter R Galle, Naoshi Nishida, Bernhard Scheiner, Fionnuala Crowley, Linda Wu, Celina Ang, Thomas U Marron, Wei-Fan Hsu, Chun-Yen Lin, Ryan Po-Ting Lin, Susanna V Ulahannan, Haripriya Andanamala, Noha Soror, Ahmed Kaseb, Michael Lapelusa, Yehia I Mohamed, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Brooke Wietharn, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Tiziana Pressiani, Andrea Dalbeni, Leonardo Natola, Mariarosaria Marseglia, Fabio Piscaglia, Yi-Hsiang Huang, Pei-Chang Lee, Mario Pirisi, Alessandro Parisi, Natascha Rohlen, Robert Thimme, Marianna Silletta, Emanuela Di Giacomo, Bruno Vincenzi, Luca Galbato, Arndt Vogel, Giuseppe Cabibbo, Calogero Camma, Hong Jae Chon, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Valentina Zanuso, Lorenza Rimassa, David J Pinato, Eric O Aboagye, Rohini Sharma. The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study. The Lancet Digital Health 2026; 8(2): 100952 doi: 10.1016/j.landig.2025.100952
|
| 21 |
Maoyuan Zhang, Kunlong Yang, Jiyun Zhang, Tingting Mo, Yijing Chen, Chuwen Zhong, Sihao Chen, Jingtong Zhang, Min Ye, Ting Zhou, Chunmei Chen, Qiao Chen. Prognostic predictive value of the preoperative systemic immunoinflammatory index combined with the neutrophil‑to‑lymphocyte ratio in patients with primary liver cancer undergoing transarterial chemoembolization. Oncology Letters 2025; 30(3): 1 doi: 10.3892/ol.2025.15160
|
| 22 |
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors. Cancers 2024; 16(6): 1225 doi: 10.3390/cancers16061225
|